October 2021 OSE Immunotherapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
October 2021 OSE Immunotherapeutics and ARCAGY-GINECO Announce First Patient Randomized in Phase 2 Clinical Trial Evaluating Tedopi®
October 2021 Servier and OSE Immunotherapeutics Announce Enrollment of First Patient in OSE-127/S95011 Phase 2 Clinical Trial
October 2021 OSE Immunotherapeutics Announces Voluntary Pause of Enrollment in the CoVepiT Phase 1 Study
October 2021 OSE Immunotherapeutics Announces Manufacturing Agreement with Cenexi for Clinical Batches of CoVepiT
October 2021 OSE Immunotherapeutics Reports on its 2021 Virtual Combined General Shareholder’s Meeting